FDA clears new AI software for brain aneurysm detection
The U.S. Food and Drug Administration has cleared a new imaging artificial intelligence software for brain aneurysm detection, the product’s developers announced Friday.
Uptunity was designed to support radiologists and other physicians in spotting signs of this clinical concern on CT angiography, along with aiding in follow-up assessments. The software was developed by contrast-agent manufacturer Bracco in collaboration with Avicenna.AI.
The two note that 1 in every 50 U.S. adults suffer an unruptured brain aneurysm, a condition that is often asymptomatic and difficult to detected on images.
"A small incidental aneurysm on a head CTA can easily be overlooked when the work list keeps growing,” Cosimo DePinto, executive VP of marketing and commercial operations for Bracco Americas, said in a statement Nov. 13. "Uptunity Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan. The clinical decision stays where it belongs: with the radiologist."
The software helps identify suspected saccular brain aneurysms greater than 3 mm on head CTA images and provides info about their presence, location and size for assessment and characterization. Plus, for known aneurysms, its follow-up functions deliver quantitative measurements and comparisons between exams to help physicians assess changes over time.
Bracco emphasized that the algorithm is not intended to replace a full in-person patient evaluation, nor a qualified radiologist’s image review. Avicenna.AI and the Milan, Italy-based company first signed their partnership— aimed at enhancing contrast-based CT—back in March 2026. They’re now preparing for the commercial launch of Uptunity in the U.S., with Avicenna leading promotion and distribution.
